ARTICLE | Clinical News

VX-770: Phase IIa started

October 25, 2010 7:00 AM UTC

Vertex began a 3-part, double-blind, international Phase IIa trial to evaluate a combination of CFTR regulators VX-770 and VX-809 in up to 160 patients with 2 copies of the delta F508 CFTR mutation. In the first part of the trial, 2 arms will receive once-daily 200 mg VX-809 alone for 14 days, followed by 150 or 250 mg VX-770 every 12 hours with continued VX-809 treatment for 7 days. The third arm will receive placebo for 21 days. After an analysis of data from the first part of the trial, Vertex said it may conduct up to 2 additional parts of the trial to evaluate higher doses of VX-809. ...